Pfizer and Chinese Biotech Company Team Up

NetVation DL Medicine (DL Medicine), a biopharmaceutical company based in China, has scored a two-year collaboration deal with Pfizer, one of the largest companies in the industry. Together, these companies will conduct research into innovative treatments for patients around the world. Furthermore, the deal allows Pfizer to take a financial stake in the Chinese company.
What Will the Companies Research?
Even before this deal with Pfizer, DL Medicine partnered with HitGen to access the company’s DNA-encoded library. The latest partnership will allow all companies involved to leverage this database to discover new interventions for a variety of illnesses.
“We are delighted to announce this collaboration with Pfizer, and we look forward to working together to potentially discover new chemical entities for the treatment of diseases that negatively impact the health of patients worldwide,” said Dr. Wei Chen, the CEO of DL Medicine. As the former leader of drug discovery at HitGen, Chen is intimately familiar with the DNA-encoded library and the program’s potential.
As is the nature of these deals, the exact cures and treatments this partnership may produce is a mystery. However, DL Medicine has made breakthroughs in metabolic, inflammatory, and cancer-related diseases in the past. It’s likely that we’ll continue to see innovation in those areas.
Why Pfizer Invested
As part of this agreement, Pfizer made a serious financial investment in the smaller company, DL Medicine. Yuan-Hua Ding, the Executive Director of External Science and Innovation at Pfizer, believes this research will help the global business heal more patients than ever before.
“New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world,” he said. “This collaboration represents our worldwide commitment to partnering with companies that are doing innovative scientific work to help enhance our portfolio across multiple disease areas.”
Why China?
It’s probably no accident that Pfizer chose a China-based company as its partner in this endeavor. Not only is DL Medicine uniquely qualified to take on this project, but the company is also situated in a booming research and development market. Over the past 20 years, China has become a global leader in scientific discovery. In fact, the country has soared past both the United States and the European Union in this area regarding money spent and outcomes.
The newfound partnership between DL Medicine and Pfizer may bring about some critical medical advancements. Learn more about DL Medicine and Pfizer to follow this significant deal.

Follow us on social media for the latest updates in B2B!

Image

Latest

healthcare system
The Sustainability of the Healthcare System
December 3, 2025

The sustainability of the healthcare system won’t be secured by another round of cost-cutting or clever benefit design alone, but by a hard cultural pivot toward alignment: payers, providers, employers, and patient advocates pulling on the same rope instead of grading each other on different exams. Right now we’ve built a maze that…

Read More
Allow Doctors to Provide Care Without Making Patients Fight the Insurance System
December 3, 2025

Patients shouldn’t have to become their own case managers just to access a hip replacement, transplant, or any other life-changing procedure; the moment they’re pushed into a paperwork fight, the system has already shifted its burden onto the sick. In a functional healthcare model, clinicians and their teams handle the insurer negotiations behind…

Read More
Physician Advisors
The Impact of Physician Advisors on Hospital Revenue and Patient Advocacy in a Payer-First Era
December 3, 2025

Physician advisors are becoming the quiet linchpin of hospital resilience in a reimbursement environment where insurers increasingly treat care like a spreadsheet exercise. As payers tighten criteria and automate denials, the gap between clinical reality and business logic widens—and without a skilled physician advisor (and a disciplined appeals pathway), health systems risk watching…

Read More
payer denials
How Hospitals Can Defend Against Payer Denials Without Sacrificing Patient Care
December 3, 2025

Payer denials used to feel like a series of personal affronts—clinicians and administrators trading war stories in hallways, certain they were being shortchanged but lacking the proof to do more than fume. Today, that fog should be lifting: with data warehouses, smarter analytics, and years of claims history, hospitals can pinpoint which payers…

Read More